Preeclampsia is a serious pregnancy disorder, affecting nearly 10 millionwomen globally each year, and can strike without ...

Novo Nordisk acquired rights to etavopivat when it bought Forma Therapeutics for $1.1 billion in 2022, when the drug was in ...

In a 2025 cross-industry survey, 44% of organisations reported experiencing negative consequences from generative AI use, ...

A combination regimen for kidney cancer treatment based on MSD's Welireg has failed a phase 3 trial, denting the company's ...

After years of constrained capital markets, biotech companies are operating in an environment where even late-stage ...

Jazz Pharma's Ziihera and Eli Lilly's Jaypirca, respectively – have been recommended by reimbursement agency NICE for NHS use ...

Roche could be just months away from an FDA approval of Gazyva as the first anti-CD20 therapy for systemic lupus ...

Italian drive to increase diagnosis rates in children with severe genetic disorders is achieving transformative results. The ...

Faruk Uzman is Vice President Europe, Middle East, Africa at Boston Scientific. He joined Boston Scientific in 2018 and ...

In this week's second major AI model launch for life sciences research, OpenAI has introduced GPT-Rosalind, designed to accelerate drug discovery and support biology-related research work. The launch ...

In another signal of the deepening relationship between the pharma and AI sectors, Novartis chief executive Vas Narasimhan has been appointed to the Board of Anthropic. Narasimhan, who has been at the ...

GSK has reported positive clinical results with an antibody-drug conjugate licensed from China's Hansoh Pharma in 2023, delivering an early fillip for new chief executive Luke Miels. The phase 1 ...